STING1 and melanoma: The relevance of innate immune pathways in melanoma treatment is highlighted by some immunotherapy approaches such as TLR7 in the adjuvant therapy with imiquimod (36), TLR9 in the development of the emerging agonists tilsotolimod and vidutolimod (37), STING in the case of ADU S-100 (38), and the clinical use of IFN-α (39).